자궁내막증 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Endometriosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

US $ 5,795 ￦ 8,424,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 12,785,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 17,146,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

자궁내막증 치료 시장 - 조사 범위

TMR의 조사 보고서 "자궁내막증 치료 세계 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회도 조사했습니다. 이 보고서는 2024년을 기준 연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지의 세계 자궁내막증 치료 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 자궁내막증 치료 시장의 연평균 복합 성장률(CAGR %)도 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서 분석가들은 주요 오피니언 리더, 업계 리더 및 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 자료 등을 참고하여 자궁내막증 치료 시장을 추론했습니다.

시장 스냅샷
2023년 시장 규모	14억 달러
2034년 시장 규모	31억 달러
CAGR	7.5%

이 보고서는 세계 자궁내막증 치료 시장의 경쟁 환경을 조사하고 있습니다. 세계 자궁내막증 치료 시장에서 사업을 운영하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 회사 개요, 재무 상태, 최근 동향, SWOT 등은 이 보고서에서 다루는 세계 자궁내막증 치료 시장 기업의 속성입니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 시장

제4장 시장 개요

• 소개
• 개요
• 시장 역학
• 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

• 파이프라인 분석
• 주요 제품·브랜드 분석
• 주요 M&A
• COVID-19에 의한 산업에 대한 영향

제6장 세계의 시장 분석과 예측 : 치료 유형별

• 소개와 정의
• 주요 조사 결과·발전
• 시장 금액 예측 : 치료 유형별, 2020-2034년
  • 진통제
  • 호르몬요법
• 시장 매력 분석 : 치료 유형별

제7장 세계의 시장 분석과 예측 : 약물 종류별

• 소개와 정의
• 주요 조사 결과·발전
• 시장 금액 예측 : 약물 종류별, 2020-2034년
  • 호르몬 피임약
  • 성선자극호르몬 방출 호르몬(Gn-RH) 작용제 및 길항제
  • 프로게스틴 요법
  • 아로마타제 억제제
• 시장 매력 분석 : 약물 종류별

제8장 세계의 시장 분석과 예측 : 유통 채널별

• 소개와 정의
• 주요 조사 결과·발전
• 시장 금액 예측 : 유통 채널별, 2020-2034년
  • 병원 약국
  • 소매 약국
  • 기타
• 시장 매력 분석 : 유통 채널별

제9장 세계의 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 금액 예측 : 지역별, 2020-2034년
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력 분석 : 지역별

제10장 북미의 시장 분석과 예측

제11장 유럽의 시장 분석과 예측

제12장 아시아태평양의 시장 분석과 예측

제13장 라틴아메리카의 시장 분석과 예측

제14장 중동 및 아프리카의 시장 분석과 예측

제15장 경쟁 상황

• 시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
• 시장 점유율 분석 : 기업별(2023)
• 기업 개요
  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Myovant Sciences Ltd.
  • Pfizer Inc.
  • The Takeda Pharmaceutical Company Limited
  • Lannett Co Inc
  • Teva Pharmaceutical Industries Ltd.

ksm

영문 목차

영문목차

Endometriosis Treatment Market - Scope of Report

TMR's report on the global endometriosis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global endometriosis treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global endometriosis treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the endometriosis treatment market.

Market Snapshot
Market Value in 2023	US$ 1.4 Bn
Market Value in 2034	US$ 3.1 Bn
CAGR	7.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global endometriosis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global endometriosis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global endometriosis treatment market.

The report delves into the competitive landscape of the global endometriosis treatment market. Key players operating in the global endometriosis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global endometriosis treatment market profiled in this report.

Key Questions Answered in Global endometriosis treatment Market Report:

• What is the sales/revenue generated by endometriosis treatment across all regions during the forecast period?
• What are the opportunities in the global endometriosis treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Endometriosis Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global endometriosis treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global endometriosis treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global endometriosis treatment market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Endometriosis Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Endometriosis Treatment Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product /Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Endometriosis Treatment Market Analysis and Forecast, by Treatment Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Treatment Type, 2020-2034
  • 6.3.1. Pain Medication
  • 6.3.2. Hormone Therapy
• 6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Endometriosis Treatment Market Analysis and Forecast, by Drug Class

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Drug Class, 2020-2034
  • 7.3.1. Hormonal Contraceptives
  • 7.3.2. Gonadotropin-releasing Hormone (Gn-RH) Agonists and Antagonists
  • 7.3.3. Progestin Therapy
  • 7.3.4. Aromatase Inhibitors
• 7.4. Market Attractiveness Analysis, by Drug Class

8. Global Endometriosis Treatment Market Analysis and Forecast, by Distribution Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Others
• 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Endometriosis Treatment Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2020-2034
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Endometriosis Treatment Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Treatment Type, 2020-2034
  • 10.3.1. Pain Medication
  • 10.3.2. Hormone Therapy
• 10.4. Market Value Forecast, by Drug Class, 2020-2034
  • 10.4.1. Hormonal Contraceptives
  • 10.4.2. Gonadotropin-releasing Hormone (Gn-RH) Agonists and Antagonists
  • 10.4.3. Progestin Therapy
  • 10.4.4. Aromatase Inhibitors
• 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Retail Pharmacies
  • 10.5.3. Others
• 10.6. Market Value Forecast, by Country, 2020-2034
  • 10.6.1. U.S.
  • 10.6.2. Canada
• 10.7. Market Attractiveness Analysis
  • 10.7.1. By Treatment Type
  • 10.7.2. By Drug Class
  • 10.7.3. By Distribution Channel
  • 10.7.4. By Country

11. Europe Endometriosis Treatment Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Treatment Type, 2020-2034
  • 11.3.1. Pain Medication
  • 11.3.2. Hormone Therapy
• 11.4. Market Value Forecast, by Drug Class, 2020-2034
  • 11.4.1. Hormonal Contraceptives
  • 11.4.2. Gonadotropin-releasing Hormone (Gn-RH) Agonists and Antagonists
  • 11.4.3. Progestin Therapy
  • 11.4.4. Aromatase Inhibitors
• 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
  • 11.5.1. Hospital Pharmacies
  • 11.5.2. Retail Pharmacies
  • 11.5.3. Others
• 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 11.6.1. Germany
  • 11.6.2. U.K.
  • 11.6.3. France
  • 11.6.4. Italy
  • 11.6.5. Spain
  • 11.6.6. Rest of Europe
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Treatment Type
  • 11.7.2. By Drug Class
  • 11.7.3. By Distribution Channel
  • 11.7.4. By Country/Sub-region

12. Asia Pacific Endometriosis Treatment Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Treatment Type, 2020-2034
  • 12.3.1. Pain Medication
  • 12.3.2. Hormone Therapy
• 12.4. Market Value Forecast, by Drug Class, 2020-2034
  • 12.4.1. Hormonal Contraceptives
  • 12.4.2. Gonadotropin-releasing Hormone (Gn-RH) Agonists and Antagonists
  • 12.4.3. Progestin Therapy
  • 12.4.4. Aromatase Inhibitors
• 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
  • 12.5.1. Hospital Pharmacies
  • 12.5.2. Retail Pharmacies
  • 12.5.3. Others
• 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.6.1. China
  • 12.6.2. Japan
  • 12.6.3. India
  • 12.6.4. Australia & New Zealand
  • 12.6.5. Rest of Asia Pacific
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Treatment Type
  • 12.7.2. By Drug Class
  • 12.7.3. By Distribution Channel
  • 12.7.4. By Country/Sub-region

13. Latin America Endometriosis Treatment Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Treatment Type, 2020-2034
  • 13.3.1. Pain Medication
  • 13.3.2. Hormone Therapy
• 13.4. Market Value Forecast, by Drug Class, 2020-2034
  • 13.4.1. Hormonal Contraceptives
  • 13.4.2. Gonadotropin-releasing Hormone (Gn-RH) Agonists and Antagonists
  • 13.4.3. Progestin Therapy
  • 13.4.4. Aromatase Inhibitors
• 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
  • 13.5.1. Hospital Pharmacies
  • 13.5.2. Retail Pharmacies
  • 13.5.3. Others
• 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.6.1. Brazil
  • 13.6.2. Mexico
  • 13.6.3. Rest of Latin America
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Treatment Type
  • 13.7.2. By Drug Class
  • 13.7.3. By Distribution Channel
  • 13.7.4. By Country/Sub-region

14. Middle East & Africa Endometriosis Treatment Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Key Findings
• 14.3. Market Value Forecast, by Treatment Type, 2020-2034
  • 14.3.1. Pain Medication
  • 14.3.2. Hormone Therapy
• 14.4. Market Value Forecast, by Drug Class, 2020-2034
  • 14.4.1. Hormonal Contraceptives
  • 14.4.2. Gonadotropin-releasing Hormone (Gn-RH) Agonists and Antagonists
  • 14.4.3. Progestin Therapy
  • 14.4.4. Aromatase Inhibitors
• 14.5. Market Value Forecast, by Distribution Channel, 2020-2034
  • 14.5.1. Hospital Pharmacies
  • 14.5.2. Retail Pharmacies
  • 14.5.3. Others
• 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 14.6.1. GCC Countries
  • 14.6.2. South Africa
  • 14.6.3. Rest of Middle East & Africa
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Treatment Type
  • 14.7.2. By Drug Class
  • 14.7.3. By Distribution Channel
  • 14.7.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2023)
• 15.3. Company Profiles
  • 15.3.1. AbbVie Inc.
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. SWOT Analysis
    • 15.3.1.4. Financial Overview
    • 15.3.1.5. Strategic Overview
  • 15.3.2. AstraZeneca plc
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. SWOT Analysis
    • 15.3.2.4. Financial Overview
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Bayer AG
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. SWOT Analysis
    • 15.3.3.4. Financial Overview
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Ferring Pharmaceuticals
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. SWOT Analysis
    • 15.3.4.4. Financial Overview
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Johnson & Johnson
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. SWOT Analysis
    • 15.3.5.4. Financial Overview
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Myovant Sciences Ltd.
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. SWOT Analysis
    • 15.3.6.4. Financial Overview
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Pfizer Inc.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. SWOT Analysis
    • 15.3.7.4. Financial Overview
    • 15.3.7.5. Strategic Overview
  • 15.3.8. The Takeda Pharmaceutical Company Limited
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. SWOT Analysis
    • 15.3.8.4. Financial Overview
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Lannett Co Inc
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. SWOT Analysis
    • 15.3.9.4. Financial Overview
    • 15.3.9.5. Strategic Overview
  • 15.3.10. Teva Pharmaceutical Industries Ltd.
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Product Portfolio
    • 15.3.10.3. SWOT Analysis
    • 15.3.10.4. Financial Overview
    • 15.3.10.5. Strategic Overview

관련자료